Phage-display peptides as novel antimicrobial agents against
View Patent ↗Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae . These peptides were able to inhibit growth of both H. influenzae and Staphylococcal aureus . Thus, methods for treating bacterial infections, alone or in combination with traditional antibiotics, are envisioned.
1. A method for inhibiting the growth of a Staphylococcal or Haemophilus species comprising contacting said species with a peptide comprising the sequence.
2. The method of claim 1 , wherein said species is a Staphylococcal species.
3. The method of claim 2 , wherein said Staphylococcal species is S. aureus.
4. The method of claim 1 , wherein said species a Haemophilus species.
5. The method of claim 4 , wherein said Haemophilus species is H. influenzae.
6. The method of claim 5 , wherein said H. influenzae species is non-typeable H. influenzae.
7. The method of claim 1 , wherein said peptide is between 15 and about 50 residues in length.
8. The method of claim 1 , wherein said peptide is between 15 and about 25 residues in length.
9. The method of claim 1 , wherein said peptide is 15 residues in length.
10. The method of claim 1 , further comprising contacting said species with a chemopharmaceutical antibiotic.
11. A method for treating a Staphylococcal or Haemophilus species bacterial infection in a subject comprising contacting said subject with a peptide comprising the sequence KQRTSIRATEGCLPS (SEQ ID NO:4) in an amount sufficient to inhibit the growth of bacteria in vivo.
12. The method of claim 11 , wherein said Staphylococcal species is S. aureus.
13. The method of claim 11 , wherein said Haemophilus species is H. influenzae.
14. The method of claim 13 , wherein said H. influenzae species is non-typeable H. influenzae.
15. The method of claim 11 , wherein said peptide is between 15 and about 50 residues in length.
16. The method of claim 11 , wherein said peptide is between 15 and 25 residues in length.
17. The method of claim 11 , wherein said peptide is 15 residues in length.
18. The method of claim 11 , wherein said peptide is delivered locally or regionally to a site of infection.
19. The method of claim 18 , wherein said peptide is administered to a wound site.
20. The method of claim 18 , wherein said peptide is administered topically.
21. The method of claim 11 , wherein said peptide is delivered systemically.
22. The method of claim 21 , wherein said peptide is delivered via intravenous or intraarterial injection.
23. The method of claim 11 , further comprising administering to said subject a chemopharmaceutical antibiotic.
24. A method for preventing a Staphylococcal or Haemophilus bacterial infection in a subject comprising contacting said subject with a peptide comprising the sequence KQRTSIRATEGCLPS (SEQ ID NO:4) in an amount sufficient to inhibit the growth of bacteria in vivo.
25. A method for preventing Staphylococcal or Haemophilus bacterial growth in a solution comprising mixing said solution with a peptide comprising the sequence KQRTSIRATEGCLPS (SEQ ID NO:4) in an amount sufficient to inhibit the growth of bacteria in said solution.
26. A method for preventing Staphylococcal or Haemophilus bacterial attachment or growth on an abiotic surface comprising coating said surface with a peptide comprising the sequence KQRTSIRATEGCLPS (SEQ ID NO:4) in an amount sufficient to inhibit the growth of bacteria on said abiotic surface.
27. The method of claim 26 , wherein said surface is part of a medical device.
28. The method of claim 27 , wherein said medical device is a syringe, a stent, a catheter, fluid container, a pacemaker, or an implantable pump.
29. A medical device, a surface of which is coated with a peptide comprising the sequence KQRTSIRATEGCLPS (SEQ ID NO:4) in an amount sufficient to inhibit the growth of Stayhylococcal or Haemophilus bacteria in vivo.
30. The device of claim 29 , wherein said medical device is a syringe, a stent, a catheter, fluid container, a pacemaker, a bandage, or an implantable pump.
31. The device of claim 29 , wherein said medical device is coated with a second antibiotic agent.
32. An isolated peptide of 15 to about 50 residues comprising the sequence KQRTSIRATEGCLPS (SEQ ID NO:4).
33. A method for identifying a Staphylococcal or Haemophilus bacterial receptor comprising:
(a) providing a sample suspected of comprising a bacterial receptor;
(b) providing a peptide comprising the sequence KQRTSIRATEGCLPS (SEQ ID NO:4);
(c) contacting said sample with said peptide; and
(d) identifying a receptor that binds to said peptide.
34. The method of claim 33 , wherein said sample is a whole bacterium.
35. The method of claim 33 , wherein said sample is a bacterial cell wall.
36. The method of claim 33 , wherein said peptide is fixed to a support.
37. The method of claim 36 , wherein said support is a filter, a column, a bead, a dipstick or a gel.
38. The method of claim 33 , further comprising degradative sequencing of said identified receptor.
39. The method of claim 38 , further comprising designing a degenerative probe based on the sequence of said identified receptor.
40. The method of claim 39 , further comprising using said degenerative probe to identify the gene encoding said identified receptor.